155 related articles for article (PubMed ID: 31997425)
1. Efficacy and safety of pixantrone for the treatment of multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas.
Sancho JM; Navarro B; Soler Campos JA; de Oteyza JP; de Barrenetxea Lekue C; Bregni M; Grasso Cicala S; Spione M; Mombiedro C; Soler B; Zinzani PL
Eur J Haematol; 2020 May; 104(5):499-508. PubMed ID: 31997425
[TBL] [Abstract][Full Text] [Related]
2. Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
Długosz-Danecka M; Hus I; Puła B; Jurczyszyn A; Chojnacki T; Blajer-Olszewska B; Drozd-Sokołowska J; Raźny M; Romejko-Jarosińska J; Taszner M; Jurczak W
Pharmacol Rep; 2019 Jun; 71(3):473-477. PubMed ID: 31003160
[TBL] [Abstract][Full Text] [Related]
3. NICE guidance on pixantrone monotherapy for multiply relapsed or refractory aggressive non-Hodgkin lymphoma.
Landells LJ; Prescott C; Hay N; Sutcliffe F; Stevens A
Lancet Oncol; 2014 Apr; 15(4):381-2. PubMed ID: 24818252
[No Abstract] [Full Text] [Related]
4. Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper.
Zinzani PL; Corradini P; Martelli M; Minotti G; Oliva S; Spina M; Barosi G; Tura S
Eur J Haematol; 2016 Dec; 97(6):554-561. PubMed ID: 27124765
[TBL] [Abstract][Full Text] [Related]
5. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial.
Pettengell R; Coiffier B; Narayanan G; de Mendoza FH; Digumarti R; Gomez H; Zinzani PL; Schiller G; Rizzieri D; Boland G; Cernohous P; Wang L; Kuepfer C; Gorbatchevsky I; Singer JW
Lancet Oncol; 2012 Jul; 13(7):696-706. PubMed ID: 22652183
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and Safety of Pixantrone for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Every-Day Clinical Practice: The Italian Cohort of the PIXA Registry.
Zinzani PL; Bregni M; Spione M; Mitterer M; Musuraca G; Bugli A; Piazza F; Pinto A
Acta Haematol; 2021; 144(3):259-263. PubMed ID: 33040061
[TBL] [Abstract][Full Text] [Related]
7. Pixantrone maleate for non-Hodgkin's lymphoma.
Mukherji D; Pettengell R
Drugs Today (Barc); 2009 Nov; 45(11):797-805. PubMed ID: 20126672
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Response and Remission with Pixantrone in Patients with Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma: Post-Hoc Analysis of the Multicenter, Open-Label, Randomized PIX301 Trial.
Pettengell R; Coiffier B; Egorov A; Singer J; Sivcheva L
Clin Drug Investig; 2018 Jun; 38(6):527-533. PubMed ID: 29564722
[TBL] [Abstract][Full Text] [Related]
9. Results of a multicentre UK-wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphoma.
Eyre TA; Linton KM; Rohman P; Kothari J; Cwynarski K; Ardeshna K; Bailey C; Osborne WL; Rowntree C; Eden D; Shankara P; Eyre DW; Jasani P; Chaidos A; Collins GP; Hatton CS
Br J Haematol; 2016 Jun; 173(6):896-904. PubMed ID: 26956150
[TBL] [Abstract][Full Text] [Related]
10. Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma.
Keating GM
Drugs; 2016 Oct; 76(16):1579-1586. PubMed ID: 27757832
[TBL] [Abstract][Full Text] [Related]
11. Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial.
Pettengell R; Sebban C; Zinzani PL; Derigs HG; Kravchenko S; Singer JW; Theocharous P; Wang L; Pavlyuk M; Makhloufi KM; Coiffier B
Br J Haematol; 2016 Sep; 174(5):692-9. PubMed ID: 27118109
[TBL] [Abstract][Full Text] [Related]
12. Pixantrone: merging safety with efficacy.
Papadatos-Pastos D; Pettengell R
Expert Rev Hematol; 2013 Feb; 6(1):25-33. PubMed ID: 23373776
[TBL] [Abstract][Full Text] [Related]
13. Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohort.
Srokowski TP; Liebmann JE; Modiano MR; Cohen GI; Pro B; Romaguera JE; Kuepfer C; Singer JW; Fayad LE
Cancer; 2011 Nov; 117(22):5067-73. PubMed ID: 21681734
[TBL] [Abstract][Full Text] [Related]
14. Pixantrone: a novel anthracycline-like drug for the treatment of non-Hodgkin lymphoma.
Boyle EM; Morschhauser F
Expert Opin Drug Saf; 2015 Apr; 14(4):601-7. PubMed ID: 25716061
[TBL] [Abstract][Full Text] [Related]
15. The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphomas: summary of the scientific assessment of the committee for medicinal products for human use.
Péan E; Flores B; Hudson I; Sjöberg J; Dunder K; Salmonson T; Gisselbrecht C; Laane E; Pignatti F
Oncologist; 2013; 18(5):625-33. PubMed ID: 23615696
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma.
Jamal-Hanjani M; Pettengell R
Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1441-8. PubMed ID: 21905966
[TBL] [Abstract][Full Text] [Related]
17. Pixantrone: a novel aza-anthracenedione in the treatment of non-Hodgkin's lymphomas.
El-Helw LM; Hancock BW
Expert Opin Investig Drugs; 2007 Oct; 16(10):1683-91. PubMed ID: 17922631
[TBL] [Abstract][Full Text] [Related]
18. The Cost-effectiveness of Pixantrone for Third/Fourth-line Treatment of Aggressive Non-Hodgkin's Lymphoma.
Muszbek N; Kadambi A; Lanitis T; Hatswell AJ; Patel D; Wang L; Singer JW; Pettengell R
Clin Ther; 2016 Mar; 38(3):503-15. PubMed ID: 26856929
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma.
Hübel K
Expert Opin Pharmacother; 2018 Nov; 19(16):1829-1834. PubMed ID: 30269614
[TBL] [Abstract][Full Text] [Related]
20. Pixantrone for the treatment of aggressive non-Hodgkin lymphoma.
Mukherji D; Pettengell R
Expert Opin Pharmacother; 2010 Aug; 11(11):1915-23. PubMed ID: 20569087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]